Optical coherence tomography (OCT) developer NinePoint Medical has begun a clinical trial to evaluate high-resolution optical imaging of Barrett's esophagus using the company's Nvision VLE imaging system.
The observational trial is designed to evaluate the efficacy of Nvision VLE to visualize subsurface tissue in patients undergoing esophagogastroduodenoscopy for suspected or confirmed Barrett's esophagus, which can lead to esophageal cancer.
The trial is expected to enroll approximately 100 patients at five medical centers worldwide, including the Mayo Clinic in Jacksonville, FL, and Rochester, MN; Kansas University Medical Center; Academic Medical Center in Amsterdam; University College London; and University Hospital in Nantes, France.
Nvision VLE received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January.
In other company news, NinePoint Medical hired Patrick MacCarthy as vice president of marketing. MacCarthy most recently served as vice president of marketing for Olympus America's endoscopy division.
